{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:27:41Z","timestamp":1774672061592,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1053\/cgh.2003.50015","type":"journal-article","created":{"date-parts":[[2003,3,20]],"date-time":"2003-03-20T14:33:27Z","timestamp":1048170807000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease"],"prefix":"10.1053","volume":"1","author":[{"given":"Gerassimos J.","family":"Mantzaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Petraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sfakianakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Archavlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Christidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Chadio-Iordanides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Triadaphyllou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/cgh.2003.50015_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000016938","article-title":"Impact of inflammatory bowel disease on health-related quality of life","volume":"17","author":"Casellas","year":"1999","journal-title":"Dig Dis"},{"key":"10.1053\/cgh.2003.50015_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00042737-200105000-00017","article-title":"Influence of inflammatory bowel disease on different dimensions of quality of life","volume":"13","author":"Casellas","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/cgh.2003.50015_bib3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/003655200451199","article-title":"Quality of life study in a regional group of patients with Crohn's disease. A structured interview study","volume":"35","author":"Guassora","year":"2000","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"10.1053\/cgh.2003.50015_bib4","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/ibd.3780070506","article-title":"Approach to corticosteroid-dependent and corticosteroid-refractive Crohn's disease","volume":"7","author":"Lichtenstein","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/cgh.2003.50015_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0277-9536(85)90308-9","article-title":"The meaning of medications: another look at compliance","volume":"20","author":"Conrad","year":"1985","journal-title":"Soc Sci Med"},{"key":"10.1053\/cgh.2003.50015_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1590-8658(00)80010-9","article-title":"Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh the benefits?","volume":"32","author":"Su","year":"2000","journal-title":"Dig Liver Dis"},{"key":"10.1053\/cgh.2003.50015_bib7","series-title":"Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease","author":"Sandborn","year":"2000"},{"key":"10.1053\/cgh.2003.50015_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2165\/00003495-199550050-00006","article-title":"Budesonide. A review of its pharmacological properties therapeutic efficacy in inflammatory bowel disease","volume":"50","author":"Spencer","year":"1995","journal-title":"Drugs"},{"key":"10.1053\/cgh.2003.50015_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/dtb.1997.35430","article-title":"Controlled-release budesonide in Crohn's disease","volume":"35","author":"Anonymous","year":"1997","journal-title":"Drug Ther Bull"},{"key":"10.1053\/cgh.2003.50015_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/cgh.2003.50015_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.1053\/cgh.2003.50015_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"L\u00f6fberg","year":"1996","journal-title":"Gut"},{"key":"10.1053\/cgh.2003.50015_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"key":"10.1053\/cgh.2003.50015_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/cgh.2003.50015_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2165\/00003495-200059040-00016","article-title":"Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1053\/cgh.2003.50015_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2036.2001.00942.x","article-title":"A 10-year survey of inflammatory bowel diseases\u2014drug therapy, costs and adverse reactions","volume":"15","author":"Blomqvist","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/cgh.2003.50015_bib18","first-page":"3124","article-title":"Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties","volume":"46","author":"Trom","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/cgh.2003.50015_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.35.8.1081","article-title":"Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis","volume":"35","author":"Schreiber","year":"1994","journal-title":"Gut"},{"key":"10.1053\/cgh.2003.50015_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0016-5085(95)90327-5","article-title":"Prophylactic mesalazine treatment decreases postoperative recurrence of Crohn's disease","volume":"109","author":"McLeod","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib24","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1053\/cgh.2003.50015_bib26","series-title":"Stagraphics user's guide","author":"STSC PLUS*WARE software product","year":"1986"},{"key":"10.1053\/cgh.2003.50015_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/cgh.2003.50015_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00054725-200008000-00004","article-title":"Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"6","author":"Irvine","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/cgh.2003.50015_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/BF02064179","article-title":"Quality-of-life results of a double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease","volume":"40","author":"Singleton","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1053\/cgh.2003.50015_bib30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/cgh.2003.50015_bib31","article-title":"Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life","author":"Thomsen","year":"2001"},{"key":"10.1053\/cgh.2003.50015_bib32","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","article-title":"Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease","volume":"28","author":"Irvine","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356503700226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356503700226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:56:16Z","timestamp":1761540976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356503700226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S1542356503700226"],"URL":"https:\/\/doi.org\/10.1053\/cgh.2003.50015","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/cgh.2003.50015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 American Gastroenterological Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}